1165 Preclinical evaluation of fully human bispecific antibody-drug candidates targeting HER3 and the juxtamembrane region of MUC1

• Yi Yang,
• Nannan Wang,
• W Frank An,
• Chaoshe Guo,
• Chengzhang Shang,
• Yifu Zhang,
• Gao An

Affiliations

Yi Yang

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Nannan Wang

3 Department of Epidemiology and Biostatistics, Nanjing Medical University School of Public Health, Nanjing, Jiangsu, China

W Frank An

2Biocytogen Boston Corp., Wakefield, MA, USA

Chaoshe Guo

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Chengzhang Shang

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Yifu Zhang

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Gao An

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China